for the consumer durables hitherto incorporated in the negative list. They have imported and thereby they have spent the foreign exchange, but they could not earn that much foreign exchange through the exports. We have the list. That is one aspect. I would like to know whether they have examined that or the Minister is prepared to submit the list of each exporter granted such import licences under that scheme.

Part 3 is that they are allowing the import of such consumer durables which are being produced here and which can well be purchased here. To that extent it is impairing the growth of indigenous industries. So, my question is to what extent the impact is. This is what my colleague wanted to know.

SHRI P. J. KURIEN : These special import licences which I have referred to are given only when the export obligation is fulfilled. So, there is no question of monitoring. We give the licences only after they complete the exports. Before that we do not give licences. This is with regard to special import licences.

Drug Companies involved in Overcharging of Drug Prices

*146. SHRI ANANT RAM JAISWAL:†
SHRI H. HANUMANTHAPPA:

Will the PRIME MINISTER be pleased to state :

(a) what was the import of raw materials and spares at C.I.F. cost as well as amount remitted on dividends and spent on travels by drug companies after the announcement of Drug Policy 1987, yearwise; which were the companies involved in the cases of overcharging and therefore, liable to pay under D.P.E.A.;

(b) what was the profit before tax, net fixed assets and investment made by such companies each year during the above period;

(c) what is the period upto which overcharged amount has been assessed and upto what period assessment is to be made in each case; and

(d) what are the names of products of each company which were under price control and have been exempted under DPCO, 1987 and what was the earlier and present price of each such products ?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN) :

(a) to (d) A statement is laid on the Table of the Rajya Sabha.

(a) and (c) The details regarding import of raw materials and spares, amount remitted on dividends and spent on travels are not monitored in this Department. The list of companies involved in the cases of overcharging and therefore liable to pay under the DPEA and the position in regard to assessment of liability towards the DPEA, are contained in the enclosures to the answer to the Rajya Sabha Starred Question No. 142 answered today.

(b) Details to the extent available are given in Annexure-I (See below). These pertain to the overall operations of the companies including pharmaceutical activities.

(d) To the extent information is available the details are given in the statement at Annexure-II.

†The question was actually asked on the floor of the House by Shri Anant Ram Jaiswal.

Annexure—I

(Rs. in '000')

S. No.	Name of the company	1988-89		1989-90		1990-91	
		PBT*	NFA+	PBT	NFA	PBT	NFA
1	2	3	4	5	6	7	8
1.	M/s Cyanamid .	40391	79266	67845	78820	81334	95284
2.	M/s Hoechst .	NA	640870	106993	802397	79221	1430006
3.	M/s Merind .	6653	32420	13747	39018	18023	42899
4.	M/s Pfizer .	13390	126274	69044	116077	64095	128299
5.	M/s Tamil Nadu Dada	6079	32593	4726	37077(—)	7764	45195
6.	M/s Anil Starch .	9661	111129	10160	116395	1993	111063
7.	M/s Glaxo .	100165	592148	152199	752105	164975	840024
8.	M/s Sandoz .	37651	172643	88152	169260	94354	173144
9.	M/s Parke Davis .	50604	68124	52101	65806	64017	71057
10.	M/s Burroughs Wellcome	85868	103167	27164	112739	44275	119745
11.	M/s Lyka Labs .	10113	51869	11931	59065	4087	88932
12.	M/s Carews .	15228	101704	17944	102331	20543	101016
13.	M/s Bayers .	149248	230614	83191	319295	137442	406224
14.	M/s Astra-IDL .	11598	34756	15547	34455	28249	33311
15.	M/s Themis .	1311	35837(—)	6498	44695	29766	35026
16.	M/s Alembic .	20225	219336	19698	235055	20519	270034
17.	M/s Albert David	12989	72337	9027	127995	3720	124735
18.	M/s Cadila .	47208	81203	10069	109431	31852	131161
19.	M/s German Remedies	9759	85023	62711	103377	29567	174987
20.	M/s Fulford .	NA	NA	13351	11809	13351	11809
21.	M/s Nicholas .	NA	55522	35327	69108	67865	294638
22.	M/s Boots .	73507	71601	82064	98347	98901	135787

*PBT: Profit Before Tax.
+NFA: Net Fixed Assets.

Annexure-II

Sl. No.	Name of the Company	Name of the Drug	Unit	Price before DPCO 1987 (Rs.)	Present price (Rs.)
1	2	3	4	5	6
1.	M/s Hoechst . .	Glybenclamide	Kg.	2458.00	7183.00
2.	Tamil Nadu Dadha .	Calcium Lactate	Kg.	13.85	30.50
3.	Anil Starch . .	Dextrose Anhydrous	Kg.	13.00	30.50
4.	M/s. S.G. Pharma .	Oxyphenbutazone	Kg.	696.72	870.00
5.	M/s. Ethnor . .	Tetramisole	Kg.	919.00	N.A.
6.	M/s. Pfizer . . .	Protinex	225	18.51	50.47 (for 200 gm. pack)
7.	M/s. Tablets (I) Ltd.	Oxyphenbutazone	Kg.	696.72	870.00

श्री अनन्त राम जायसवाल : माननीय सभापति जी, सरकार की गलतियों और कमियों को छिपाने के लिए हर सवाल का जवाब दबाया जाता है। ये पूरी सभा गवाह है और अपने कार्यकाल के अल्प समय में आपने स्वयं अनुभव किया होगा कि हर सवाल का जवाब दबाया जाता है। यहां चाहे जितनी कोशिश की जाए, प्रधानमंत्री को लिखा जाए, लेकिन कोई असर होता दिखाई नहीं देता। इस सवाल के जवाब का पहला ही पैरा आप देख लें, उसमें इनफारमेशन दबाई गई है। इसलिए मेरी दरख्वास्त है कि इस सवाल को पोस्टपोन करवाइए और अगली दफा इस पर जवाब दिलवाइए। ये मेरी दरख्वास्त है और प्रोटेस्ट भी है जितनी भी इनफारमेशन है, सब इनके पास मौजूद है लेकिन जवाब नहीं आता है।

MR. CHAIRMAN : Why don't you ask your supplementary question which will elicit a reply from the Government ?

SHRI ANANT RAM JAISWAL : Yes. I am prepared for that.

क्या मंत्री जी यह बतायेंगे कि जितनी भी औषध निर्माता कंपनियां हैं और दवाओं का जो कानून है, ड्रग्ज कंट्रोल का, उसके तहत क्या सारी कंपनियां फार्म 6 और फार्म 4 में और अपनी बैलेंस शीट में वह सारी जानकारी आपके कार्यालय में नहीं देती हैं जिनके बारे में यह सवाल किया गया है। क्या यह बात सही है और अगर सही है तो आपने यह कैसे जवाब दे दिया कि —

SHRI CHINTA MOHAN : The hon. Member has asked for details regarding import of raw materials and spares and amounts remitted on dividends and spent on travels by drug companies. Actually the Department of Chemicals is not monitoring this. The Department of Commerce is looking after this work. We have written to the Department of Commerce to give us the details. We would also ask the drug companies to furnish all the details of travels to different countries. Once we get the information, we will be able to give that.

SHRI ANANT RAM JAISWAL : I am dismayed by the reply. I request you to have this question adjourned for the next day.

MR. CHAIRMAN : Second supplementary, please.

SHRI ANANT RAM JAISWAL : There is no time, Sir.

MR. CHAIRMAN : May I call the next person, if you agree ?

श्री अनन्त राम जायसवाल : सभापति महोदय, दूसरी चीज में यह जानना चाहता हूं कि कितनी कम्पनियों का एसेसमेंट पूरा हो चुका है और कब पूरा हुआ और क्या यह सही है कि लगभग 240 करोड़ रुपये की लायबिलिटी एसेस की गई और उसमें से केवल लगभग 16 करोड़ रुपये वसूल किए गए। तो जो बाकी बचा है उसके लिए आपने कलक्टर को मालगुजारी की तरह वसूल करने के लिए कोई कार्रवाई की या उस पर कोई इंटरेस्ट चार्ज किया ? इसी का दूसरा पार्ट ..... (व्यवधान)

THE PRIME MINISTER (SHRI P. V. NARASIMHA RAO) : This has been answered already in the previous question.

श्री अनन्त राम जायसवाल : क्या बताया आपने ? ..... (व्यवधान)

MR. CHAIRMAN : I am sorry the Question Hour is over.